Početna › Akutna mijeloična leukemija › Iowa
Kliničke studije za Akutna mijeloična leukemija u državi Iowa
17 studija za Akutna mijeloična leukemija traži sudionike na lokacijama u državi Iowa.
Gradovi u državi Iowa
Službeni tekst studije (engleski)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- i još 12
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 40 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
U tijeku regrutacijaFaza 2
Od 18 do 59 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic, Clive
- Iowa Methodist Medical Center, Des Moines
- i još 7
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
U tijeku regrutacijaFaza 2
Od 18 do 59 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Blank Children's Hospital, Des Moines
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
U tijeku regrutacijaFaza 3
6 Months – 21 Years · Oba spola · Ažurirano 17. ruj 2026. · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- University of Iowa Hospital, Iowa City
U tijeku regrutacijaFaza 1/2
30 Days · Oba spola · Ažurirano 16. ruj 2026. · NCT04065399Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Blank Children's Hospital, Des Moines
U tijeku regrutacijaFaza 3
Od 1 do 25 godina · Oba spola · Ažurirano 4. ruj 2026. · NCT07022678A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- University of Iowa Hospital and Clinics, Iowa City
U tijeku regrutacijaOpažajna studija
Od 0 godina i više · Oba spola · Ažurirano 2. ruj 2026. · NCT07154823High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
- University of Iowa Health Care, Iowa City
U tijeku regrutacijaFaza 1
Od 18 do 75 godina · Oba spola · Ažurirano 31. kol 2026. · NCT07177079The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Blank Children's Hospital, Des Moines
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
U tijeku regrutacijaFaza 1/2
Do 22 godina · Oba spola · Ažurirano 25. kol 2026. · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- University of Iowa Stead Family Children's Hospital, Iowa City
U tijeku regrutacijaFaza 3
29 Days – 21 Years · Oba spola · Ažurirano 24. kol 2026. · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Iowa, Iowa City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 20. kol 2026. · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- University of Iowa Hospitals & Clinics, Iowa City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 20. kol 2026. · NCT06001788Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- University of Iowa Hospitals and Clinics, Iowa City
U tijeku regrutacijaFaza 3
Od 18 do 75 godina · Oba spola · Ažurirano 17. srp 2026. · NCT05429632A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Iowa, Iowa City
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 6. srp 2026. · NCT01351545A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Iowa Hospitals & Clinics, Iowa City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. ožu 2026. · NCT05735184Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.